Skip to content
Governance Register

← US public companies

Zentalis Pharmaceuticals, LLC

SEC CIK 1725160 · ZNTL · last insider filing 2026-06-18

Directors (from insider filings)

NameCapacity as filedFilings
Myers Scott Dunseth Director filed 2024 - 2026
Walker Luke Nathaniel Director filed 2024 - 2026
Johnson David Michael Director filed 2020 - 2026
Skvarka Jan Director filed 2022 - 2026
Kariuki Enoch Director filed 2021 - 2026
Campbell Shannon Director filed 2026 - 2026
Eastland Julia Marie Director · CEO & President filed 2024 - 2026
Matrix Capital Management Company, LP Director filed 2020 - 2025
Goel David E. Director filed 2020 - 2025
Gallagher Cam Director · President, Interim CFO filed 2020 - 2024
Hausman Diane Director · Chief Medical Officer filed 2023 - 2024
Blackwell Kimberly Director · President & CEO filed 2020 - 2024
SUN Anthony Y Director · President & CEO filed 2020 - 2022
Takhar Karan S. Director filed 2020 - 2020

Officers (from insider filings)

NameTitle as filedFilings
Bruns Ingmar Chief Medical Officer filed 2024 - 2026
Vultaggio Vincent Principal Accounting Officer filed 2024 - 2026
Bucher James B Chief Legal Officer filed 2025 - 2026
Lackner Mark Chief Scientific Officer filed 2024 - 2025
Paul Andrea General Counsel filed 2022 - 2025
Epperly Melissa B, Chief Financial Officer filed 2020 - 2024
Bunker Kevin D. Chief Scientific Officer filed 2020 - 2023
Brownstein Carrie Chief Medical Officer filed 2022 - 2023
Roth Iris Chief Operating Officer filed 2023 - 2023
Voliotis Dimitris SVP, Clinical Development filed 2020 - 2022
Pinto Alexis Chief Legal Officer filed 2020 - 2022

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.